Long-term pharmacokinetics of amprenavir in combination with delavirdine in HIV-infected children.
Five heavily pretreated HIV-infected children were put on amprenavir and delavirdine plus two nucleoside inhibitors to reverse transcriptase to boost amprenavir levels and to use the antiretroviral activity of a non-nucleoside reverse transcriptase inhibitor. No data are available about this combination in children. It w;as well tolerated, and the median reduction in viral load was 1.5 log after 18 months. Delavirdine boosted amprenavir trough levels more than 10-fold, and delavirdine trough levels remained i several fold above susceptible HIV strains.
Engelhorn
C
C
Department of Immunodeficiency Diseases, Childrens Hospital of the Ludwig Maximilians University, Munich, Germany.
Hoffmann
F
F
Kurowski
M
M
Stocker
H
H
Kruse
G
G
Notheis
G
G
Belohradsky
B H
BH
Wintergerst
Uwe
U
D000293:Adolescent; D019380:Anti-HIV Agents / Q000493:pharmacokinetics*; D019540:Area Under Curve; D002219:Carbamates; D002648:Child; D020008:Delavirdine / Q000493:pharmacokinetics*; D004338:Drug Combinations; D005663:Furans; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D018894:Reverse Transcriptase Inhibitors / Q000493:pharmacokinetics*; D013449:Sulfonamides / Q000493:pharmacokinetics*
D019380:Anti-HIV Agents; D002219:Carbamates; D004338:Drug Combinations; D005663:Furans; D018894:Reverse Transcriptase Inhibitors; D013449:Sulfonamides; C095108:amprenavir; D020008:Delavirdine